56984-35-1

Usage

Functional groups

Ester functional groups

Structure

Brominated benzene ring

Applications

a. Building block in organic synthesis
b. Production of polymers and plastics
c. Plasticizer or cross-linking agent
d. Development of pharmaceuticals, agrochemicals, and specialty chemicals

Reactivity

Versatile reactivity and ability to introduce functional groups

Health risks

Potential health risks, should be handled with care

Usage environment

Controlled environment by trained professionals

Upstream product

• 64-17-5 ethanol 
• 6939-93-1 4-bromo-isophthalic acid 
• 583-70-0 1-bromo-2,4-dimethylbenzene 
• 887757-25-7 4-bromo-3-cyanobenzoic acid 
• 2840-29-1 3-amino-4-bromobenzoic acid 

Downstream Products

• 1351958-72-9 C₂₅H₃₆O₄ 
• 1351958-73-0 C₂₆H₃₈O₄ 
• 1351958-64-9 1,8-bis(2,4-bis(bromomethyl)phenyl)octane 
• 1351958-65-0 1,9-bis(2,4-bis(bromomethyl)phenyl)nonane 
• 1351958-66-1 1,10-bis(2,4-bis(bromomethyl)phenyl)decane 
• 1351958-61-6 1,8-bis(2,4-bis(ethoxycarbonyl)phenyl)octane 
• 1351958-62-7 1,9-bis(2,4-bis(ethoxycarbonyl)phenyl)nonane 
• 1351958-63-8 1,10-bis(2,4-bis(ethoxycarbonyl)phenyl)decane 
• 1351958-71-8 C₂₄H₃₄O₄ 
• 1351958-60-5 1,10-bis(2,4-bis(ethoxycarbonyl)phenyl)deca-1,9-diyne 
• 1351958-59-2 1,9-bis(2,4-bis(ethoxycarbonyl)phenyl)nona-1,8-diyne 
• 1351958-58-1 1,8-bis(2,4-bis(ethoxycarbonyl)phenyl)octa-1,7-diyne 
• 925931-65-3 diethyl 4-(thiophen-3-yl)isophthalate 
• 1160184-16-6 ethyl 6-bromo-1-(4-methoxyphenyl)-3-oxo-1,3-dihydro-2-benzofuran-5-carboxylate 

Relevant academic research and scientific papers

Four congenetic zinc(II) MOFs from delicate solvent-regulated strategy: Structural diversities and fluorescent properties

Four new congenetic zinc(II) MOFs, namely [Zn5(bdcpp)3(DMF)(H2O)4]n·x(solvent) (1), [Zn2(bdcpp)(Hbdcpp)]n·y(solvent) (2), [Zn2(bdcpp)(DMF)(H2O)2]

Synthesis, crystal structure, and resolution of [10](1,6)pyrenophane: An inherently chiral [n]cyclophane

A synthetic approach to a set of three inherently chiral [n]cyclophanes, [n](1,6)pyrenophanes (29a-c, n = 8-10) was investigated. Progress toward 29a was thwarted by the failure of the key dithiacyclophane-forming reaction. For the next higher homologue, the synthesis was completed, but the desired [9](1,6)pyrenophane (29b) could only be partially separated from an isomeric pyrenophane, [9](1,8)pyrenophane (28b), and an unidentified byproduct. Work aimed at the synthesis of the next higher homologue resulted in the isolation of a 7:4 mixture of [10](1,8)pyrenophane (28c) and [10](1,6)pyrenophane (29c), which could not be separated by column chromatography or crystallization. However, single-crystal X-ray structures of 28c and 29c were obtained after manual separation of two crystals with different morphologies from the same batch of crystals obtained from the 7:4 mixture of 28c and 29c. The pyrene system of 29c was found to have a gentle end-to-end bend as well as a significant longitudinal twist. Short intermolecular C(sp3)- H???π contacts (2.64 to 2.76 A) between H-atoms on the bridge and the centroids of three of the four six-membered rings of the pyrene system of a neighboring pyrenophane of like chirality give rise to the formation of single enantiomer columns. From a DNMR study of the mixture of 28c and 29c, the bridge in [10](1,8)pyrenophane (28c) was found to undergo a conformational flip from one side of the pyrene system to the other with ΔG = 14.9 ± 0.2 kcal/mol. A two-stage preparative HPLC protocol was subsequently developed for the separation of 28c and 29c (Chiralpak AD-H column) and then the enantiomers of 29c (Chiralcel OJ-H column). This enabled the measurement of their optical rotations and CD spectra.

A novel class of inhibitors for human steroid 5α-reductase: Phenoxybenzoic acid derivatives. I

In a search for novel nonsteroidal inhibitors of human prostatic 5α- reductase, we found anew series of phenoxybenzoic acid derivatives to be potent human prostatic 5α-reductase inhibitors. Among them, 4-(biphenyl-4- yloxy)benzoic acid derivatives (2n, YM